Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

Google, Novartis Collaborate to Develop Smart Lenses

Search king Google Inc. (GOOGL - Free Report) recently declared that it has signed a definitive agreement with pharmaceutical firm, Novartis (NVS - Free Report) to create smart contact lenses for diabetics to monitor their blood sugar levels and help farsighted people improve their eyesight. Financials of the agreement were not disclosed.

Per the agreement, Google X, Google’s research division, will provide Novartis’ Alcon eye-care division the smart contact lens technology to make and commercialize a series of ocular medical products.

The lenses will be enclosed with small electronics, non-invasive tiny sensors, and microchips, which will help diabetics track insulin-levels, measure tear fluid in the eye and enable vision correction in farsighted people.

The deal will help Google leverage Alcon’s dominance in the eye-care market and its expertise in contact lenses and intraocular lenses to boost its smart contact lens product line. This will enable the tech giant to extend its footprint in fast-growing wearable technology and software products used to track health and well-being.

Last month, Google launched its Google Fit platform to monitor health metrics, such as sleep and exercise, on products running its Android operating system, a move to take on Apple Inc.’s (AAPL - Free Report) similar platform called HealthKit.

With an increasing number of health issues, more and more people are opting to take control of their own medical treatment. Moreover, over the coming years, the adoption of this non-traditional approach is going to increase. Therefore, the move is likely to benefit Google in the healthcare applications arena going forward.

The product is currently in the works and the first prototypes are expected to be launched next year. The commercialization of the lens is expected to happen within the next five years.

Resources

Client Support

Follow Us

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

Copyright 2017 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25% per year. These returns cover a period from 1988-2016 and were examined and attested by Baker Tilly Virchow Krause, LLP, an independent accounting firm. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zack Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.